Updating our readers more on the Bayer Patent Linkage case, the Supreme Court today has admitted a special leave petition filed by Bayer. (For a more detailed report, see here ). We thank our reader Manish for bringing this to our notice.
The case seems to be gaining more momentum owing to the apprehensions surrounding patent linkage as it potentially undermines the public health safeguards.The matter,as report earlier,has been listed in the third week of April for further hearing.Hopefully,the wait will be worth it.
Dear Mr.Bashir: I was curious Unlike the dasatinib case where the delhi hc gave an ex parte injuction, why the same was not done in the cipla vs bayer case and cipla also receive an injuction?
See United States Supreme Court decision on copyright poool and author’s right delivered recently.
http://www.supremecourtus.gov/opinions/09pdf/08-103.pdf
and latest Harvard law Review Article on Intellectual Property as Sumptuary Code at http://www.harvardlawreview.org/issues/123/february10/Article_6838.php
why hetero got an ex parte injuction in dasatinib case from delhi hc and cipla did not in the sorafenib case